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Neutralization testsThe hemagglutination inhibition (HI) assay has been used for the antigenic characterization of influenza
viruses for decades. However, the majority of recent seasonal influenza A viruses of the H3N2 subtype has
lost the capacity to agglutinate erythrocytes of various species. The hemagglutination (HA) activity of
other A(H3N2) strains is generally sensitive to the action of the neuraminidase inhibitor oseltamivir,
which indicates that the neuraminidase and not the hemagglutinin is responsible for the HA activity.
These findings complicate the antigenic characterization and selection of A(H3N2) vaccine strains, calling
for alternative antigenic characterization assays. Here we describe the development and use of the
ViroSpot microneutralization (MN) assay as a reliable and robust alternative for the HI assay. Serum neu-
tralization of influenza A(H3N2) reference virus strains and epidemic isolates was determined by auto-
mated readout of immunostained cell monolayers, in a format designed to minimize the influence of
infectious virus doses on serum neutralization titers. Neutralization of infection was largely independent
from rates of viral replication and cell-to-cell transmission, facilitating the comparison of different virus
isolates. Other advantages of the ViroSpot MN assay include its relative insensitivity to variation in test
dose of infectious virus, automated capture and analyses of residual infection patterns, and compatibility
with standardized large scale analyses. Using this assay, a number of epidemic influenza A(H3N2) strains
that failed to agglutinate erythrocytes, were readily characterized antigenically.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Influenza viruses are an important cause of respiratory tract
infections. Antigenic variation of the hemagglutinin (HA) allows
these viruses to evade recognition by virus-specific neutralizing
antibodies induced upon previous infection or vaccinations, and
cause epidemic outbreaks annually.
Current influenza epidemics are caused by influenza A viruses
of the H3N2 and H1N1 subtypes and influenza B viruses. The influ-
enza A viruses are descendants of the pandemic strains of 1968 and
2009 respectively [1]. Two antigenically distinct lineages of influ-
enza B viruses co-circulate since the mid 80s, spurring the develop-
ment of quadrivalent influenza vaccines, containing components of
both influenza A subtypes and both influenza B lineages [2].The efficacy of influenza vaccines depends on the antigenic
match between the vaccine and circulating strains. Because of
the antigenic drift of influenza viruses, vaccine strains are annually
selected, and when necessary updated, to match epidemic strains
predicted to circulate in the following season. However, mismatch
may occur, as during the 2014/2015 influenza season, resulting in
reduced vaccine effectiveness [3–5].
The hemagglutination inhibition (HI) assay has been used for
the antigenic characterization of influenza viruses, for decades.
For this assay, mono-specific antisera against Reference and repre-
sentative epidemic influenza strains are produced in ferrets upon
experimental infection. Serial serum dilutions are incubated with
a standard amount of the respective viruses and the highest dilu-
tion that still prevents the virus from agglutinating erythrocytes
is recorded. This method proved instrumental for influenza vaccine
strain selection and update for many years [1,6]. Although the
method is still successful for the antigenic characterization of influ-
enza A(H1N1) and B-viruses, problems have arisen with that of A
(H3N2) viruses. This is mainly caused by evolutionary changes in
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chicken or turkey erythrocytes. As an alternative, erythrocytes of
mammalian species, like human type O or guinea pig erythrocytes,
have been used. However, although A(H3N2) viruses displayed
some HA activity with mammalian erythrocytes, in many cases this
activity proved to be sensitive to the addition of the neuraminidase
(NA) inhibitor oseltamivir, indicating that NA, and not HA, was
responsible for binding to the erythrocytes and mediated HA activ-
ity [7].
These issues have raised interest in alternative assays that can
be used for the antigenic characterization of influenza viruses, such
as virus neutralization (VN) assays [8,9]. In these assays, ideally a
standard number of infectious units (e.g. 100 50% tissue culture
infectious dose (TCID50)) is incubated with serial dilutions of
serum samples. Residual non-neutralized virus is detected by inoc-
ulation of susceptible cells, in most cases Madin-Darby canine kid-
ney (MDCK) cells. The infection of these cells is assessed by
monitoring the development of cytopathic changes, or by detecting
viral protein synthesis using enzyme-linked immunosorbent assay
(ELISA) [10,11] or immunostaining of virus-infected cells [8].
Here we describe the ViroSpot microneutralization (MN) assay
as a novel assay with favorable properties and its use for the anti-
genic characterization of epidemic A(H3N2) influenza viruses,
which may aid vaccine strain selection.2. Materials and methods
2.1. Cells
MDCK cells were cultured in Eagle minimal essential medium
(EMEM; Lonza, Verviers, Belgium) containing 20 mM HEPES buffer
(Lonza), 0.075% sodium bicarbonate solution (Lonza), 2 mM
L-glutamine (Lonza), 100 IU/ml penicillin-100 lg/ml streptomycin
(Lonza), referred to as complete medium (CM), supplemented with
10% fetal bovine serum (FBS; Bodinco BV, Alkmaar, The Nether-
lands). The cells were passaged to new culture flasks twice weekly.
Two days before inoculation, the cells were seeded at a concentra-
tion of about 104/well in flat-bottom 96-well tissue culture-treated
microplates (Greiner Bio-One, Alphen aan den Rijn, The
Netherlands).
2.2. Viruses and serum samples
Epidemic influenza viruses that were isolated in the Nether-
lands were obtained from the repository of the Dutch National
Influenza Center. Ref. virus strains were provided by The Francis
Crick Institute, Mill Hill Laboratory, The Crick Worldwide Influenza
Center and The National Institute for Biological Standards and Con-
trol (NIBSC), London. All viruses were propagated in MDCK cells
cultured in infection medium (IM; complete medium without
FBS, and with 3 lg/ml tosyl phenylalanyl chloromethyl ketone
(TPCK)-treated trypsin (Sigma-Aldrich, Zwijndrecht, The Nether-
lands)). Infectious titers of the virus stocks were determined in
MDCK cells as described previously [12], or with minor modifica-
tions using half-log or five-fold dilutions and the ViroSpot
immunostaining described herein. In brief, confluent monolayers
of MDCK cells were inoculated with replicate (n = 4) serial 3.16-
fold or 5-fold dilutions of virus stocks in IM in 96-well microtiter
plates. After 90 min at 35 C in a humidified 5% CO2 incubator,
the inocula were removed and the cells washed with IM. The cells
were then cultured for 2 days in a humidified incubator at 35 C
and 5% CO2. On each plate wells with uninfected cells were
included as negative controls. As positive controls, cells infected
with one of at least two reference virus strains, were included in
each experiment.Post-infection Ref. sera were produced in ferrets essentially
as described previously [13]. Before and two weeks after intra-
nasal inoculation, blood was drawn and serum collected. A
sheep high titer standard serum directed to influenza virus A/
Texas/50/2012 was obtained from NIBSC, and used for initial
set-up of the assay.
2.3. ViroSpot microneutralization (MN) assay
Serum samples were pretreated with receptor destroying
enzyme (RDE) by incubating 100 ll of serum with 500 ll of an
in-house produced filtrate of Vibrio cholera for 16 h at 37 C, and
heat-inactivated for one hour at 56 C. The pretreated serum was
diluted to 1 ml with IM for a 1:10 dilution. Sera showing a high
homologous titer were further diluted (e.g. to 40 or 320) to
ensure that the dilution representing the titer was detected on
the test plate. Subsequently, serial dilutions were made with IM
in round-bottom plates and 60 ll of each dilution was mixed with
60 ll of virus suspension at the desired concentration of infectious
units (e.g. 100 TCID50/50 ll, as calculated from TCID50 stock titers
that were determined by using serial five-fold dilutions). After one
hour at 35 C, 100 ll of the mixtures was transferred to MDCK cells
that were washed once with phosphate buffered saline (PBS) and
once with IM. After an incubation for 90 min at 35 C, the virus-
antibody mixtures were removed, cells were washed once with
IM and overlayed with 1.6% carboxymethylcellulose (medium vis-
cosity, CMC, Sigma) in CM with 2 lg/ml modified trypsin (TPCK-
treated), and cultured for 2 days at 35 C and 5% CO2. CMC is used
to restrict viral spread in the cell monolayers. In each assay, unin-
fected control cells were included as well as virus controls without
serum incubation. The virus test dose was confirmed by back titra-
tion. To this end, serial half-log or five-fold dilutions were used to
inoculate MDCK cells in duplicates, and were processed in parallel
to the serum assay plates.
Next, the cells were washed at least twice with PBS to remove
the CMC overlay and 100 ll 10% formalin (Sigma) was added to
the wells. After 15 min at room temperature, or at least 16 h at
4 C, or up to 30 days at 20 C, the formalin was removed and
plates were washed once with PBS. The variable formalin fixation
times allow for completion of small-scale experiments with a
few plates on the day of fixation on the one hand, and for process-
ing large batches of plates within the timeframe of several days or
weeks on the other hand. A volume of 100 ll of 0.5% Triton X-100
(Applichem GmbH, Darmstadt, Germany) was added and the plates
were incubated for 10 min at room temperature. After washing the
plates with PBS, ViroSpot immunostaining was performed by incu-
bating the formalin-fixed and permeabilized cells for one hour at
room temperature with 50 ll of a mouse monoclonal antibody
(HB65; EVL, Woerden, The Netherlands) directed against the viral
nucleoprotein (NP), followed by a one hour incubation at room
temperature with 50 ll of a horseradish peroxidase-labeled goat
anti mouse immunoglobulin preparation (GAM-HRPO, Invitrogen,
Foster city, CA). Antibody reagent dilutions were made in PBS con-
taining 2% (w/v) Skimmed Milk Powder (Sigma), and optimized for
each reagent lot. HB65 (2 mg/ml) and GAM-HRPO (1 mg/ml) were
used at 1/20,000 and 1/10,000 dilutions respectively. After each
incubation step, the plates were washed three times with PBS con-
taining 0.05% Tween-20. After the last washing step, 50 ll of True-
Blue substrate (KPL, Gaitherburg, Maryland) was added per well
and incubated for 10 min at room temperature. The plates were
washed four times with distilled water, the last time for 30 min.
After drying, the plates were submitted to automated image cap-
ture using a Series 6 ImmunoSpot Image Analyzer (CTL Immuno-
Spot, Cleveland OH, USA) to quantitate the percentage well area
covered by spots of infected cells. The percentage inhibition was
calculated according to the following formula:
Table 1
Microneutralization (MN) assay formats: comparison of similarities and differences that impact basic virological principles and assay robustness of WHO MN and ViroSpot MN.
Process WHO MN ViroSpot MN
Infectious virus
titration
Concentration of virus stocks (infectious
units)
1 unit = the dilution factor required for 2 higher
signal than uninfected cells in 50% of cultures
1 unit = the dilution factor required to infect
50% of cultures (TCID50)
Incubation temperature and period 18–20 h at 37 C; irrespective of virus replication
kinetics
Until all infected wells become positive;
1–2 days at 35 C, depending on replication
kinetics
Test virus
preparation
Dilution factor To obtain 100 infectious units/well To obtain 100 TCID50/well
Target concentration (TCID50/well) Depends on kinetics of virus replication and cell-to-
cell transmission
100
Expected range around 100 (TCID50/well) Unknown 20–500
Neutralization
method
Mix virus and serum 60 min 60 min
Indicator cells (MDCK) to monitor
infection/neutralization
Add cells to virus/serum mixtures Add virus/serum mixtures to confluent
monolayer of cells
Replace inoculum with overlay medium No Yes (1.6% CMC after 90 min)
Incubation 18–20 h at 37 C (INF A) 1–2 days at 35 C
Fixation of cells Acetone Formalin
Detection of virus propagation NP-ELISA (soluble TMB) NP-immunostaining (precipitating TMB)
Signal OD450-620 nm Well area covered
Neutralization cut-off 650% 690%
Rationale for cut-off Evidence of neutralization Exclude variability around 100%
Neutralization of
different
viruses
Amount of test virus depends on
replications kinetics
Yes No
Effect of variation in TCID50 on the amount
of serum required for neutralization
Variable Low
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where
X is the value of well area covered by spots of infected cells (%
WAC) in wells inoculated with virus/serum mixtures.
CC is the average of %WAC in the cell control wells (no virus).
VC is the average of %WAC in the virus-control wells (no
serum).
Inhibition P90% was considered positive for neutralization.
When viruses were back titrated, the number of infectious units
were determined by counting immunostained plaque forming
units (PFU) at dilutions that resulted in easily countable number
of plaques per well (approximately between 10 and 60). The test
dose of virus was considered acceptable if it was between 14 and
345 PFU/well, which corresponds to 20 and 500 TCID50/well and
is ± one dilution step around the target dose of 100 TCID50/well
when 5-fold dilutions were used for stock virus titration.
2.4. WHO MN assay
Previously, a MN assay was described to circumvent some of the
HI assay-related issues [10]. This MN assay has been adopted by
the WHO for serologic analyses. In the present study on antigenic
typing, the assay was carried out essentially as described in the
WHO Manual for the laboratory diagnosis and virological surveil-
lance of influenza [11]. The same NP-specific monoclonal antibody
and GAM-HRPO were used as described above for ViroSpot
immunostaining, but in a volume of 200 ll of a 1/3,000 and
1/30,000, respectively, for use with TMB substrate (Sigma). An
overview of characteristics and differences of the WHO MN and
ViroSpot MN assay is presented in Table 1.
2.5. HI assay
After treatment with RDE from in-house cholera filtrate and
heat-inactivation at 56 C, the sera were tested for the presence
of anti-HA antibodies by HI assay using standard protocols for
serological diagnosis [11], with modifications for antigenic typing.
In brief, 50 ll of serially diluted pretreated serum samples wereincubated with four hemagglutinating units of virus in the pres-
ence of Oseltamivir carboxylate (Roche, Basel, Switzerland; end
concentration 20nM). After 30 min at 37 C, 25 ll of 1% guinea
pig erythrocyte (Bio Trading, Mijdrecht, The Netherlands) suspen-
sion in PBS containing 1% BSA (Invitrogen) was added. Agglutina-
tion patterns were read by two technicians independently after
an incubation period of 2 h at 4 C.
3. Results
3.1. Receptor destroying enzyme
During earlier attempts to develop the Virospot (VS) MN assay,
some pre-infection ferret sera showed non-specific neutralization
of virus (Fig. 1). Pre-treatment of serumwith a filtrate of Vibrio cho-
lera as a source of RDE, successfully prevented this non-specific
non-antibody-mediated inhibition, by effectively removing HA
receptor molecules from serum components. Post-infection serum
retained its capacity to neutralize the virus with titers similar to
those of untreated serum samples. An example of the effect of
RDE treatment is shown in Fig. 1. Similar findings were obtained
with five other ferret serum pairs obtained with 3 different viruses
(X-187, IVR-165 and X223A). Thus, RDE treatment of serum sam-
ples is recommended for use in VS MN assay to prevent non-
specific neutralization of virus.
3.2. Sensitivity of ViroSpot and WHO MN assays to variations in
quantity of input virus
To allow meaningful and reliable antigenic comparison of dif-
ferent virus strains, it is imperative that a standardized quantity
of input virus is used for each of the viruses tested. Indeed, the
level of neutralization of each virus tested by a reference serum
depends on the quantity of infectious units present during the
course of the antigenic typing assay. For the HI assay, this is rela-
tively easily achieved by using 4 hemagglutinating units of virus.
For MN assays, the infectious virus titer of each virus stock needs
to be determined. Assessment of infectious virus titers is subject
to variability, which is generally accepted within ±1 dilution step
from the mean titer. Following a single experiment, the true titer
A/Victoria/ 361/2011 (IVR-165)
serum pre-infecon post-infecon
dilution No RDE RDE No RDE RDE
10
20
40
80
160
320
VC
CC
640
1280
2560
5120
10.240
20.480
VC
CC
Fig. 1. Receptor destroying enzyme (RDE) removes non-specific inhibition from
pre- and post-infection sera obtained from a ferret experimentally infected with
influenza virus A/Victoria/361/2011 (IVR-165). Sera were tested in triplicate. Red
box: Highest dilution of post-infection ferret serum showingP 90% inhibition. VC:
virus control; CC: cell control.
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one dilution step. Virus test doses aiming at 100 TCID50 are there-
fore expected to range between 20 and 500 TCID50, if the original
stock titration was based on a five-fold dilution series.
To compare the effect of differences in input virus quantity on
WHO MN and Virospot MN assay measurements, we performed
both assays with influenza virus A/Texas/50/2012 using 10–600
TCID50 per well and a sheep antiserum raised against this virus.
As shown in Table 2, the geometric mean titers (GMT) measured
in the WHO MN assays ranged from 45,255 when 10 TCID50 of
virus was used to 8,000 when P300 TCID50 was used. Based on
the WHO MN criteria for back titration values, only the 30 and
100 TCID50 cultures lay within the acceptable range. For 300
TCID50, the WHO MN titer was 8,000, which is already 4-fold
lower than observed with a 10-fold higher virus concentration. InTable 2
Sensitivity of MN assay results for variability in virus concentration.
A/Tex/50/2012 (TCID50/well) WHO MN assaya (20 h IM + serum)
Replicate 1 MN titer Replicate 2 MN titer
10 64,000 32,000
30 32,000 32,000
100 16,000 16,000
300 8,000 8,000
450 8,000 8,000
600 8,000 8,000
a Cells were added to virus/serum mixtures in infection medium (IM) and incubated
b GMT: geometric mean titer.
c BT: Back-titration result in accordance with acceptation criteria: Y = yes, N = No.
d Virus/serum mixtures were added to cells for 90 min and replaced with IM + 1.6%
immunostaining.contrast, the GMT MN titers measured in the ViroSpot MN assay
differed no more than 2-fold using the same virus suspensions
ranging from 10 up to 450 TCID50 (Table 2 and Fig. 2). This shows
that ViroSpot MN assay results are less sensitive to variability in
input test virus concentrations. Erroneous interpretation of virus
concentration difference as an antigenic difference therefore is less
likely.3.3. Antigenic characterization of reference strains
We compared the performance of both MN assays for the anti-
genic characterization of influenza A(H3N2) viruses using selected
Ref. strains and ferret sera raised against three vaccine strains, A/
Victoria/210/2009 (X-187), A/Victoria/361/2011 (IVR-165) and A/
Texas/50/2012 (X-223A). The input virus dose was aimed at 100
TCID50. Back-titration of all Ref. and vaccine strains ranged
between 49 and 293 TCID50, within the expected ±1 dilution step
of 100 TCID50. As shown in Table 3, WHO MN and ViroSpot MN
titers correlated reasonably well. Also, the identification of anti-
genic match with the vaccine strains was in general comparable
between the two MN assays and similar to that of HI assays as
deduced from the WHO consultation reports (http://www.crick.
ac.uk/research/world-wide-influenza-Center).
However, the WHOMN assay did not produce antibody titers of
vaccine strain-specific antisera for three strains, A/Iowa/19/2010
(for one out of two sera), A/Perth/16/2009 and A/Hong
Kong/146/2013, because of unclear neutralization patterns due to
a combination of low virus signal and high serum background at
low dilutions (Table 3). For these viruses, the WHO MN virus con-
trol values were the lowest among the virus strains tested. The
respective virus test doses were 131, 142 and 49 TCID50/well, as
determined by back titration of input virus used in the ViroSpot
MN assay, within the expected range for targeted inocula of 100
TCID50. Lower signals in the WHO MN assay could have resulted
from lower infection and replication efficiency. This may be com-
pensated by testing higher virus concentrations, but this is con-
trary to the aim of comparing antigenic differences at similar
virus concentrations. The low virus signal combined with elevated
background ELISA signals at low serum dilutions resulted in false
positives in the WHO MN assay. The Virospot MN assay using
the same virus suspensions and serum dilutions provided results,
since serum background signals were inherently lower and did
not increase for lower serum dilutions. While the serum is not
removed in the WHOMN assay, contributing to higher optical den-
sity ELISA signal, serum and virus are removed following a brief
inoculation period in the VS MN assay. In addition, the WHO MN
assay readout is the optical density of a soluble substrate, whereas
the VS MN assay readout is the well area covered by a precipitating
substrate.VS MN assayd (48h IM + CMC)
GMTb BTc Replicate 1 MN titer Replicate 2 MN titer GMT
45,255 N 32,000 16,000 22,627
32,000 Y 16,000 16,000 16,000
16,000 Y 16,000 32,000 22,627
8,000 N 8,000 16,000 11,341
8,000 N 8,000 16,000 11,341
8,000 N 8,000 8,000 8,000
for 20 h prior to fixation and NP-ELISA.
carboxymethyl cellulose (CMC) for two days prior to fixation and ViroSpot (VS)
VS MN 
GMT
22,627
16,000
22,627
11,314
11,314
8,000
Fig. 2. ViroSpot MN results for six concentrations of A/Texas/50/2012 and ten two-
fold dilutions of sheep immune serum. Boxed:P90% inhibition of virus control (VC)
value in columns 1 and 2. GMT: geometric mean titer of duplicates for each virus
concentration. CC: cell control; VS MN: ViroSpot microneutralization; dpi: days
post inoculation.
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Wefurtherevaluatedtheabilityof theViroSpotMNassaytobeused
for the antigenic characterization of epidemic A(H3N2) influenza
viruses, compared to the HI assay. To this end, virus stocks of seven A
(H3N2) influenza viruses isolated between 2013 and 2015 in theTable 3
Antigenic typing of A(H3N2) reference viruses with post-infection ferret sera.
Virusa,b Back-titration WH
TCID50/wellb Serum Tite
A/Wisconsin/67/2005 63 X-187 <32
A/Uruguay/716/2007 93 X-187 <32
A/Victoria/208/2009 102 X-187 10,
A/Victoria/210/2009 X-187 162 X-187 10,
A/Wisconsin/15/2009 141 X-187 <32
A/Iowa/19/2010 139 X-187 512
A/Uruguay/716/2007 112 IVR-165 <40
A/Wisconsin/15/2009 177 IVR-165 40
A/Iowa/19/2010 131 IVR-165 ?
A/Perth/10/2010 172 IVR-165 40
A/Victoria/361/2011 IVR165 293 IVR-165 256
A/Hawaii/22/2012 66 IVR-165 128
A/Uruguay/716/2007 102 X-223A <40
A/Perth/16/2009 142 X-223A ?
A/Hawaii/22/2012 94 X-223A 128
A/Texas/50/2012 X-223A 125 X-223A 256
A/Hong Kong/146/2013 49 X-223A ?
A/South Africa/4655/2013 64 X-223A 160
a Boldface: vaccine strain.
b Back-titrations of virus test doses ranged from 49 to 293 TCID50, well within in the
c Sera were pre-diluted to obtain a dilution range extending from 32- to 64-fold lowe
d V: Vaccine strain; M: match (64-fold lower than homologous titer); N: non-match (
virus signal and high serum background.
e Based on hemagglutination inhibition (HI) documented in WHO annual consultation
wide-influenza-Center);
* If no HI data were available, status was determined during preliminary ViroSpot MNNetherlands were produced and titrated. The antibody titers of
post-infection ferret antisera raised against vaccine Ref. strains A/Vic-
toria/361/2011, A/Texas/50/2012 and A/Switzerland/9715293/2013,
and three of the epidemic strains,were determined against thehomol-
ogousandheterologousstrains (Table4).Mostof thesevirusesalsodis-
played HA activity with guinea pig erythrocytes in the presence of
oseltamivir. As shown in Table 4, in general, the antibody recognition
profiles were similar in the Virospot MN assay and the HI assay, and
corresponded to the antigenic clades the respective viruses belonged
to. For example, antisera to influenza viruses A/Victoria/361/2011
and A/Texas/50/2012, both clade 3C.1 viruses, displayed relatively
low titers to clade 3C.3 and 3C.2a viruses. The antiserum directed to
virus A/Victoria/361/2011 displayed a higher degree of cross-
reactivity, which was also observed by others [8]. Conversely, anti-
serum to clade 3C.3a virus A/Switzerland/9715293/2013 and clade
3C.2a virus A/Netherlands/1810/2015 displayed low titers to viruses
from the other clades. The virus neutralization patterns were not
caused by antibodies directed to NA, because antiserum directed to a
reverse genetics H7N2 virus [14] failed to neutralize an A(H3N2) virus
with an antigenically matching neuraminidase (data not shown). Fur-
thermore, sera raised against anunrelated type of influenza virus (type
B) did not display any non-specific neutralization of the A(H3N2)
viruses.4. Discussion
The emergence of influenza A(H3N2) viruses that fail to agglu-
tinate erythrocytes in the absence or presence of oseltamivir in
recent years, has complicated the antigenic characterization of
these viruses with the traditionally used HI assay. This problem
has been noted by us and others [8,9], and prompted the develop-
ment and use of alternative assays for this purpose, like the virus
neutralization assay.
In the late 90s, aMNassaywasdeveloped as an alternative for the
HI assay for the detection of antibodies to avian influenza viruses of
the H5N1 subtype in human serum samples [10]. However, this
assay was deemed not suitable for the antigenic characterization
of influenza viruses, because various influenza A(H3N2) virusesO MN VS MN HI assay
rc Statusd Titer Status Match Statuse
0 N <320 N N
0 N <320 N N
240 M 10,240 M M
240 V 10,240 V –
0 N 320 N N
0 M 2560 M M
N <40 N N*
N 160 N N*
? 5120 M M
N 160 N N*
0 V 2560 V –
0 M 1280 M M
N <40 N N*
? 320 N N
0 M 2560 M M
0 V 2560 V –
? 2560 M M
N 160 N N
expected range of 20–500 TCID50.
r through 2- to 4-fold higher than the homologous titer.
>4-fold lower than homologous titer); ?: Unclear neutralization pattern due to low
reports on the composition of influenza vaccines (www.crick.ac.uk/research/world-
assay testing.
Table 4
ViroSpot MN and HI-based antigenic typing of A(H3N2) epidemic virus isolates.
Virus Genetic
clade
Passage
history
HAU
(-/+ OSEL)a
A/Victoria/
361/11
A/Texas/50/
12 (X223A)
A/Swiss/
9715293/13
A/NL/2249/
13
A/NL/1810/
15
B/Phuket/
3073/13d
tRBC gRBC
- + - + VS-MNb HIc VS-MN HI VS-MN HI VS-MN HI VS-MN HI VS-MN HI
A/Victoria/361/11 3C.1 Mdck2 Siat2 Mdck4 64 0 64 8 320 480 80 640 160 320 1280 480 40 320 <20 <10
A/Texas/50/2012 (X-223A) 3C.1 E9Mdck1 32 6 32 32 2560 1920 2560 2560 320 240 640 240 320 160 <20 <10
A/Swiss/9715293/2013 3C.3a E4E1Mdck1 64 6 32 32 2560 160 640 80 >10240 960 320 80 640 120 <20 <10
A/NL/2249/2013 3C.3 Mdck3 48 0 32 1 80 nt 80 nt 80 nt 160 nt 20 nt <20 nt
A/NL/1810/2015 3C.2a Mdck2 Siat2 Mdck4 8 6 16 8 80 60 40 240 40 120 80 80 >10,240 960 <20 <10
A/NL/48/2015 3C.3 Mdck1 8 0 16 0 320 nt 80 nt 40 nt 80 nt 40 nt <20 nt
A/NL/573/2014 3C.3 Mdck1 64 0 64 6 160 240 80 320 80 240 160 240 80 240 <20 <10
A/NL/1679/2015 3C.2a Mdck1 8 0 16 16 80 60 20 60 80 80 160 80 320 320 <20 <10
A/NL/748/2014 3C.3 Mdck2 8 0 16 16 80 640 40 640 20 320 160 480 40 320 <20 <10
A/NL/1293/2015 3C.2a Mdck3 8 8 16 16 640 120 80 320 20 320 40 160 2560 320 <20 <10
a Hemagglutination units (HAU) with or without oseltamivir (OSEL) for turkey red blood cells (tRBC) or guinea pig red blood cells (gRBC).
b Boldface: homologous titer.
c HI titers with gRBC + 20 nM OSEL; nt: not tested due to limiting HA activity.
d Homologous HI titer for B/Phuket/3073/13: 1920.
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differ considerably, making the use of a classic plaque reduction
assay difficult. Recently, a modification of a plaque reduction assay
wasdescribed [8], inwhich cells are culturedunder a solidifiedmed-
ium using Avicel overlay and quantification of the infected cell pop-
ulation (ICP). The amount of virus used in this assay is adjusted to
give 20–85% infected cell area, which is also dependent on the vari-
able replication kinetics of the different viruses tested. Thus, the
amount of infectious units remains largely unknown and may vary
between virus strains. To allow comparison of influenza virus anti-
genic properties in a reproducible manner, similarly to the HI assay,
the amount of input virus ideally must be the same for each virus
tested. To address this issue, the Virospot MN assay makes use of a
standardized amount of input test viruses (100TCID50) and anover-
lay of the cells with 1.6% carboxymethyl cellulose (CMC). CMC
restricts plaque development even more so than Avicel [15], which
is advantageous in termsof creating a better dynamic range formea-
suring inhibition of infectious units, even after a 2-day incubation
period. This facilitates the testing of virus strainswith the same pro-
tocol, independently of their replication kinetics, with relatively
slow viruses able to produce sufficient signal to be detected, and at
the same time preventing incidental non-neutralized units of
rapidly replicating viruses to overgrow the entire well area. In gen-
eral itmakes sense to titrate virus preparations using the same read-
out as used in the virus neutralization assay. However, for the
determination of infectious virus titers for the purpose of antigenic
typing we consider an end-point dilution assay, i.e. a TCID50 assay,
more appropriate, since it is more robust and objective than count-
ing spots. Assessing infected and uninfected wells, as is done in the
TCID50 assay, is independent of factors that may differ between
virus isolates considerably, such as replication kinetics and spot
sizes. Of note, the TCID50 assay was performed by incubating serial
5-fold virus dilutions for a period of time sufficient to guarantee
scoring of all infectedwells as positive byViroSpot immunostaining,
even those inoculated with a single infectious unit. Consequently,
TCID50 values were independent of virus propagation kinetics and
may reflect true infectious titersmoreaccurately. Regardless, in gen-
eral back-titration values showed good agreement with the
expected inoculum concentration. An overview of the characteris-
tics and differences of the WHO MN and ViroSpot MN assay is pre-
sented in Table 1. The ViroSpot MN assay offers several favorable
properties: a standardizeddose of input test viruswith limited influ-
ence of the virus replication kinetics and cell-to-cell transmission,
limiting its sensitivity to variation in input virus dose, in contrast
to otherMN formats, and infected cells are detected in an automatedfashion, based on a precipitating substrate, suitable for high
throughput use.
Compared to the HI assay, the ViroSpot MN assay is more com-
plex and labor intensive to perform. One way to improve high
throughput testing, could be the use of a number of set virus dilu-
tions in duplicate without prior titration. Antigenic distance can
subsequently be inferred by comparing neutralization titers
between virus strains at similar virus concentrations as deter-
mined by back-titration. The use of MDCK-SIAT cell may also add
to further improve the assay. However, even in its present form,
the ViroSpot MN assay is suitable for the antigenic characterization
of epidemic virus strains and its use may aid vaccine strain selec-
tion. The results obtained with the low passage isolates indicate
that the assay can also be applied to field isolate testing. Future
testing of additional isolates is required to further assess the sensi-
tivity of the ViroSpot MN assay for this application.
Using A(H3N2) Ref. strains, which retained their capacity to
agglutinate erythrocytes and which were characterized antigeni-
cally by HI assay, the ViroSpot MN assay was shown to correctly
predict vaccine match status. The ViroSpot MN assay also proved
suitable for the antigenic characterization of A(H3N2) epidemic
strains isolated in the Netherlands during the 2014/2015 influenza
season. The majority of A(H3N2) influenza viruses isolated during
recent influenza seasons fail to agglutinate erythrocytes in the
presence of oseltamivir and therefore antigenic characterization
of these viruses solely relies on alternative (MN) assays. Antisera
raised against vaccine strain A/Texas/50/2012 displayed poor VN
antibody titers against such recent strains, which belong to genetic
clades 3C.3 and 3C.2a. Antiserum raised against a 3C.2a virus A/
Netherlands/1810/15 had high homologous titers, but failed to
neutralize viruses of the other clades efficiently, confirming that
these viruses were antigenically different. Of interest, the antigeni-
cally distinct clade 3C.2a viruses have become the dominant A
(H3N2) viruses globally [16], which prompted the WHO to recom-
mend a virus of this clade as the 2016 vaccine strain for the south-
ern hemisphere, A/Hong Kong/4801/2014 [9]. The availability of a
robust and reproducible MN assay is essential for the antigenic
characterization of recent A(H3N2) influenza viruses. The ViroSpot
MN assay offers attractive advantages over the WHO MN assay,
including the relative insensitivity to variation in amount of infec-
tious virus used in the test, independence from virus replication
kinetics, automated virospot image capture and suitability for high
throughput analyses. Of note, an infected cell population (ICP) MN
assay has recently been described [8] and it would be of interest to
compare the performance of the ViroSpot MN assay with this ICP
52 C.A. van Baalen et al. / Vaccine 35 (2017) 46–52MNassay, whichwould require amulti-center effort using the same
virus batches and serum samples. The availability of alternative VN
assays may help the timely antigenic characterization of seasonal
influenza viruses and the rapid recommendations of vaccine strains
to be used in the subsequent influenza season, considered a priority
by the WHO [17]. (http://www.who.int/influenza/vaccines/virus/
4thmtg_improve_vaccine_virus_selection/en/).Conflict of interest
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